Phase II trial of menogaril in advanced colorectal cancer

Eduard E. Holdener, Wim W. ten Bokkel Huinink, Genevieve Decoster, Christian Ludwig, Georgette Renard, Herbert M. Pinedo

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were achieved. Myelosuppression, only leukopenia, was usually of mild-moderate degree and occurred in 63% of the patients. Twenty-seven percent of the patients experienced severe leukopenia. Local erythema and phlebitis were frequently observed and were severe in 13% of the patients. Nausea/vomiting (66%) and alopecia (50%) were of mild-moderate degree. This study suggests that menogaril at these doses and schedule had no activity in advanced colorectal cancer.

Original languageEnglish (US)
Pages (from-to)227-230
Number of pages4
JournalInvestigational New Drugs
Issue number3
StatePublished - Sep 1988
Externally publishedYes


  • anthracycline
  • colorectal cancer
  • menogaril
  • phase II trial

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine


Dive into the research topics of 'Phase II trial of menogaril in advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this